Sanofi has agreed to buy exclusive global rights to develop Korean company ABL Bio’s preclinical antibody for the treatment of neurodegenerative conditions, including Parkinson’s disease. Purchase price: $75 million upfront, with additional payments that could total $1 billion.
Source: Drug Industry Daily